Cumberland Pharmaceuticals (CPIX) Other Non-Current Assets (2010 - 2026)
Cumberland Pharmaceuticals (CPIX) posted Other Non-Current Assets of $2.9 million for Q1 2026, down 1.59% sequentially from $3.0 million in Q4 2025, and up 6.71% YoY from $2.7 million in Q1 2025.
Cumberland Pharmaceuticals (CPIX) Other Non-Current Assets (2010 - 2026) Analysis & Trends
Cumberland Pharmaceuticals has reported Other Non-Current Assets for 17 years, with the latest figure at $2.9 million in Q1 2026.
- Quarterly Other Non-Current Assets rose 6.71% year-over-year to $2.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.9 million (up 6.71% YoY) and the FY2025 annual result came in at $3.0 million, up 6.8% from the prior year.
- Other Non-Current Assets fell to $2.9 million in Q1 2026 per CPIX's latest filing, from $3.0 million in the prior quarter.
- Over five years, Other Non-Current Assets peaked at $3.2 million in Q1 2022 and troughed at $2.4 million in Q3 2022.
- A 5-year average of $2.8 million and a median of $2.8 million in 2024 frame the typical range for Other Non-Current Assets.
- The sharpest annual moves came in 2022 and 2024: Other Non-Current Assets declined 27.34% in 2022, then rose 20.24% in 2024.
- Over 5 years, Other Non-Current Assets stood at $2.5 million in 2022, then increased by 6.83% to $2.7 million in 2023, then grew by 3.38% to $2.8 million in 2024, then grew by 6.8% to $3.0 million in 2025, then dropped by 1.59% to $2.9 million in 2026.
- According to Business Quant data, Other Non-Current Assets over the past three periods registered $2.9 million, $3.0 million, and $3.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | 56.35 Mn |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 1.79 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 384.00 Mn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 503.80 Mn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 239.50 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 1.06 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 59.30 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 304.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | 13.00 Mn |
| 10 | Cumberland Pharmaceuticals | 114.68 Mn | 110.82 Mn | - | 18.45 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 18.45 Mn |
| Mar 31, 2026 | 2.93 Mn |
| Dec 31, 2025 | 2.97 Mn |
| Sep 30, 2025 | 2.99 Mn |
| Jun 30, 2025 | 2.85 Mn |
| Mar 31, 2025 | 2.74 Mn |
| Dec 31, 2024 | 2.78 Mn |
| Sep 30, 2024 | 2.83 Mn |
| Jun 30, 2024 | 2.99 Mn |
| Mar 31, 2024 | 3.06 Mn |
| Dec 31, 2023 | 2.69 Mn |
| Sep 30, 2023 | 2.56 Mn |
| Jun 30, 2023 | 2.61 Mn |
| Mar 31, 2023 | 2.55 Mn |
| Dec 31, 2022 | 2.52 Mn |
| Sep 30, 2022 | 2.43 Mn |
| Jun 30, 2022 | 2.54 Mn |
| Mar 31, 2022 | 3.18 Mn |
| Dec 31, 2021 | 3.42 Mn |
| Sep 30, 2021 | 3.30 Mn |